Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

NOVAVAX INC Director's Dealing 2021

Jan 27, 2021

31982_dirs_2021-01-27_e922e8a9-dcc8-4d68-a314-4f657753d658.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4/A — Form 4/A

Issuer: NOVAVAX INC (NVAX)
CIK: 0001000694
Period of Report: 2021-01-05

Reporting Person: Trizzino John (EVP, Chief Commercial Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-01-05 Common Stock F 511 $116.24 Disposed 866 Direct

Footnotes

F1: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2: The reporting person received 579 shares of common stock upon the net exercise of 1,149 stock appreciation rights. The reporting person forfeited 59 shares of common stock underlying the stock appreciation rights representing the base value and 511 shares of common stock underlying the stock appreciation rights to satisfy the withholding tax obligations resulting from the exercise, using the closing stock price on January 5, 2021 of $116.24.

F3: This amendment to the original Form 4 filed on January 7, 2021 is being filed to correct the number of shares reported as forfeited by the reporting person to satisfy withholding tax obligations resulting from the exercise of 1,149 stock appreciation rights on January 5, 2021.